Loading...
XSTOKLAR
Market cap4mUSD
Dec 23, Last price  
0.33SEK
1D
10.37%
1Q
-57.58%
Jan 2017
-96.12%
IPO
-93.33%
Name

Klaria Pharma Holding AB (publ)

Chart & Performance

D1W1MN
XSTO:KLAR chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
25.14%
Rev. gr., 5y
20.87%
Revenues
0k
-100.00%
0002,275,000649,0004,223,0007,220,0006,112,0005,868,0000
Net income
-36m
L-43.89%
0-5,593,000-14,550,000-12,014,000-27,306,000-23,843,000-51,439,000-53,534,000-63,774,000-35,784,000
CFO
-9m
L-81.79%
-4,429,000-14,393,000-12,060,000-9,126,000-14,796,000-35,296,000-24,797,000-49,729,000-9,058,000

Profile

Klaria Pharma Holding AB (publ.) operates as a pharmaceutical company in Sweden and internationally. It offers Sumatriptan for the treatment of migraine; and Midazolam for acute epilepsy. The company's clinical phase products include Epinephrine/Adrenaline for the treatment of acute allergic reaction; Naloxone for opioid overdose; and Ketamine for acute pain and depression. It also focuses on the commercialization of cannabis/cannabinoids, including THC and CBD for medical and recreational applications. The company was founded in 2014 and is based in Uppsala, Sweden.
URL
https://www.klaria.com/
IPO date
Oct 21, 2015
Employees
6
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
5,868
-3.99%
6,112
-15.35%
Cost of revenue
14,902
61,511
78,198
Unusual Expense (Income)
NOPBT
(14,902)
(55,643)
(72,086)
NOPBT Margin
Operating Taxes
(57)
117
(11)
Tax Rate
NOPAT
(14,845)
(55,760)
(72,075)
Net income
(35,784)
-43.89%
(63,774)
19.13%
(53,534)
4.07%
Dividends
Dividend yield
Proceeds from repurchase of equity
16,371
41,734
38
BB yield
-35.15%
-61.92%
-0.01%
Debt
Debt current
18,932
16,743
30,704
Long-term debt
1,359
2,699
Deferred revenue
Other long-term liabilities
Net debt
17,685
1,341
7,912
Cash flow
Cash from operating activities
(9,058)
(49,729)
(24,797)
CAPEX
(42)
Cash from investing activities
(2)
(42)
Cash from financing activities
(6,457)
41,056
19,038
FCF
(72,985)
(55,107)
(73,514)
Balance
Cash
1,247
16,761
25,491
Long term investments
Excess cash
1,247
16,468
25,185
Stockholders' equity
(237,874)
(96,957)
(169,006)
Invested Capital
297,940
189,750
269,771
ROIC
ROCE
EV
Common stock shares outstanding
100,798
58,102
55,252
Price
0.46
-60.17%
1.16
-81.20%
6.17
-0.48%
Market cap
46,569
-30.91%
67,398
-80.23%
340,904
19.00%
EV
64,256
68,763
348,841
EBITDA
(14,893)
(44,609)
(61,121)
EV/EBITDA
Interest
3,777
7,843
3,166
Interest/NOPBT